Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 13, 2026, 4:41 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2857–2880 of 14,161 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Safety Control Clear all

Conditions: Chronic Neuropathic Pain
Interventions: ST-503, Sham (No Treatment); Genetic · Procedure
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 11
States / cities: Scottsdale, Arizona • Little Rock, Arkansas • La Jolla, California + 8 more

Conditions: Chronic Kidney Disease, Hyperparathyroidism, Secondary, Vitamin D Deficiency
Interventions: CTAP101 30 μg capsules, Sugar pill to CTAP101 30 μg capsules; Drug · Other
Lead sponsor: OPKO IP Holdings II, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Bannockburn, Illinois

Conditions: Food Allergy
Interventions: Chinese Herbal Medication, Placebo, Omalizumab, Multi OIT; Drug
Lead sponsor: Xiu-Min Li; Other
Eligibility: 6 Years to 40 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Baltimore, Maryland • New York, New York

Conditions: Age-related Macular Degeneration (AMD), Geographic Atrophy (GA)
Interventions: Pozelimab, Cemdisiran, Placebo; Drug
Lead sponsor: Regeneron Pharmaceuticals; Industry
Eligibility: 50 Years to 85 Years
Enrollment: 975 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2033
U.S. locations: 160
States / cities: Chandler, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 126 more

Conditions: Mast Cell Activation Syndrome
Interventions: Masitinib 4.5 mg/kg/day, Placebo, Best supportive care, Masitinib 6.0 mg/kg/day; Drug · Other
Lead sponsor: AB Science; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Weldon Spring, Missouri

Conditions: Staphylococcal Sepsis
Interventions: Placebo, Pagibaximab 50 mg/mL; Drug
Lead sponsor: Biosynexus Incorporated; Industry
Eligibility: Up to 48 Hours
Enrollment: 1,579 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Gaithersburg, Maryland

Conditions: Schizophrenia
Interventions: OMS643762, Placebo; Drug
Lead sponsor: Omeros Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Long Beach, California

Conditions: Allergic Conjunctivitis
Interventions: Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), Vehicle Ophthalmic Solution; Drug
Lead sponsor: Aldeyra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 318 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018
U.S. locations: 7
States / cities: Phoenix, Arizona • Sacramento, California • Torrance, California + 3 more

Conditions: Pancreatic Cancer
Interventions: Masitinib, Placebo, Gemcitabine; Drug
Lead sponsor: AB Science; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 12
States / cities: Norwich, Connecticut • Orlando, Florida • Atlanta, Georgia + 9 more

Conditions: Spinal Cord Injury (SCI)
Interventions: Elezanumab, Placebo; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 22
States / cities: Sacramento, California • Atlanta, Georgia • Chicago, Illinois + 15 more

Conditions: Diabetic Foot Ulcers
Interventions: DSC127, placebo vehicle gel; Drug
Lead sponsor: Integra LifeSciences Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 266 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 25
States / cities: Mobile, Alabama • Fair Oaks, California • Fresno, California + 22 more

Conditions: Hyperkalemia
Interventions: Sodium Zirconium Cyclosilicate; Drug
Lead sponsor: ZS Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 123 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 41
States / cities: Anniston, Alabama • Huntsville, Alabama • Scottsboro, Alabama + 35 more

Conditions: Alzheimer's Disease
Interventions: CHF5074 1x, CHF5074 2x, CHF5074 3x, Placebo; Drug
Lead sponsor: CERESPIR; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Eatontown, New Jersey

Conditions: Contraception
Interventions: Levonorgestrel/EE 0.15/0.03 mg and EE 0.01 mg tablets; Drug
Lead sponsor: Duramed Research; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 320 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2006
U.S. locations: 11
States / cities: Tucson, Arizona • Washington D.C., District of Columbia • Lincoln, Nebraska + 8 more

Conditions: Complicated Intra-abdominal Infections
Interventions: Ceftazidime -avibactam, Meropenem, Metronidazole; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 3 Months to 17 Years
Enrollment: 83 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 4
States / cities: Orange, California • San Diego, California • Toledo, Ohio + 1 more

Conditions: Acne Vulgaris
Interventions: Benzoyl peroxide gel, Clindamycin gel, Tazarotene cream, Vehicle gel, Vehicle cream; Drug
Lead sponsor: Stiefel, a GSK Company; Industry
Eligibility: 12 Years to 45 Years
Enrollment: 591 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 16
States / cities: Little Rock, Arkansas • Fremont, California • Sacramento, California + 13 more

Conditions: Constipation, Bowel Dysfunction
Interventions: alvimopan, placebo; Drug
Lead sponsor: Cubist Pharmaceuticals LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA); Industry
Eligibility: 18 Years and older
Enrollment: 233 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 69
States / cities: Tucson, Arizona • Hot Springs, Arkansas • Duarte, California + 58 more

Conditions: Temporomandibular Disorder
Interventions: Erenumab-aooe (EREN) 140 mg s.c. administered every four weeks for a total of five treatments, Placebo (EREN-P) s.c. administered every four weeks for a total of five treatments; Drug
Lead sponsor: Indiana University; Other
Eligibility: 18 Years to 59 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Myasthenia Gravis, Generalized
Interventions: zilucoplan (RA101495), Placebo; Drug
Lead sponsor: Ra Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 74 Years
Enrollment: 174 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 37
States / cities: Mobile, Alabama • Phoenix, Arizona • Los Angeles, California + 33 more

Conditions: Infertility
Interventions: Progesterone-IBSA Injectable Solution, Progesterone Vaginal Gel with Applicator, Placebo Vaginal gel with applicator, Placebo injectable solution; Drug
Lead sponsor: IBSA Institut Biochimique SA; Industry
Eligibility: 35 Years to 42 Years · Female only
Enrollment: 688 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 24
States / cities: Tempe, Arizona • Encino, California • Los Angeles, California + 20 more

Conditions: Prostatic Neoplasms
Interventions: Apalutamide, Bicalutamide, Bicalutamide Placebo, Apalutamide Placebo, GnRH (agonist), 74-80 Grays (units of radiation); Drug · Radiation
Lead sponsor: Aragon Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 1,503 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2028
U.S. locations: 60
States / cities: Homewood, Alabama • Chandler, Arizona • Scottsdale, Arizona + 57 more

Conditions: Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
Interventions: Bimekizumab, Ustekinumab, Placebo; Drug · Other
Lead sponsor: UCB Biopharma SRL; Industry
Eligibility: 18 Years and older
Enrollment: 567 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 25
States / cities: Phoenix, Arizona • Bakersfield, California • San Diego, California + 22 more

Conditions: Influenza, Influenza -Like Illness
Interventions: Norketotifen, Placebo; Drug
Lead sponsor: Emergo Therapeutics, Inc.; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 315 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 20
States / cities: Phoenix, Arizona • Los Angeles, California • DeBary, Florida + 15 more

Conditions: Rheumatoid Arthritis
Interventions: Secukinumab (AIN457), Placebo; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 637 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 39
States / cities: Mesa, Arizona • Paradise Valley, Arizona • Peoria, Arizona + 34 more

Search by objective public record fields.

Safety and Tolerability Study of ST-503 for Refractory Pain Due to Peripheral Neuropathy (Small Fiber Predominant, SFN)

Safety and Efficacy of CTAP101 to Treat Secondary Hyperparathyroidism in Stage 3 or 4 CKD and Vitamin D Insufficiency

E-B-FAHF-2, Multi OIT and Xolair (Omalizumab) for Food Allergy

A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy

Masitinib for the Treatment of Severe Mast Cell Activation Syndrome

Safety and Efficacy of Pagibaximab Injection in Very Low Birth Weight Neonates for Prevention of Staphylococcal Sepsis

Safety, Tolerability, and Pharmacokinetics of OMS643762 in Psychiatrically Stable Schizophrenia Subjects

ALLEVIATE Trial - A Phase 3 Trial in Subjects With Allergic Conjunctivitis

Masitinib in Combination With Gemcitabine for Treatment of Patients With Advanced/Metastatic Pancreatic Cancer

Safety And Efficacy Study Of Intravenous (IV) Administration Of Elezanumab To Assess Change In Upper Extremity Motor Score (UEMS) In Adult Participants With Acute Traumatic Cervical Spinal Cord Injury (SCI)

Phase III Study to Evaluate Efficacy and Safety of DSC127 in Diabetic Foot Ulcers

Open-label Safety & Efficacy of ZS (Sodium Zirconium Cyclosilicate)10g qd to Extend Study ZS-004 in Hyperkalemia.

Study to Evaluate Safety, Pharmacokinetics and Pharmacodynamics of CHF5074 in Healthy Young Male Subjects

A Multicenter Study to Evaluate the Safety of Seasonique, an Oral Contraceptive.

Evaluation of Safety,Pharmacokinetics and Efficacy of CAZ-AVI With Metronidazole in Children Aged 3 Months to 18 Years Old With Complicated Intra-abdominal Infections (cIAIs).

Safety and Efficacy Study of Clindamycin/Benzoyl Peroxide/Tazarotene Cream in Subjects With Acne

Study Of Alvimopan Drug For Treatment Of Constipation Due To Prescription Pain Medication

Safety and Efficacy of Erenumab-aooe in Patients With Temporomandibular Disorder

Safety, Tolerability, and Efficacy of Zilucoplan in Subjects With Generalized Myasthenia Gravis

Subcutaneous Progesterone in Frozen- Thawed Single Euploid Blastocyst Transfer.

An Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS

A Study to Evaluate the Efficacy and Safety of Bimekizumab Compared to Placebo and an Active Comparator in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis

Efficacy and Safety of Norketotifen in Uncomplicated Influenza-like Illness

Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents